TIDMETX
RNS Number : 9986S
e-Therapeutics plc
14 July 2020
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION
CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR RELEASE,
PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART,
DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES , AUSTRALIA ,
CANADA , JAPAN , NEW ZEALAND , THE REPUBLIC OF SOUTH AFRICA OR ANY
OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION,
OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE
OR DISPOSE OF ANY SECURITIES IN E-THERAPEUTICS PLC OR ANY OTHER
ENTITY IN ANY SUCH JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES
AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014.
14 July 2020
e-therapeutics plc
("e-therapeutics" or the "Company")
Exercise of Broker Option
Total Fundraise of GBP11.6 million
e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the
Company"), announces that further to the Fundraise announced on 7
July 2020, Numis Securities Limited has exercised the Broker Option
in respect of 2,875,000 new Ordinary Shares (the "Broker Option
Shares"), raising gross proceeds of approximately GBP0.35 million
for the Company.
The Broker Option Shares are being issued at a price of 12p per
share (being the Placing Price) and will be issued on the same
terms and conditions as the Firm Placing Shares pursuant to the
Placing.
Application will be made to the London Stock Exchange for the
2,875,000 Broker Option Shares to be admitted to trading on AIM.
Admission of the Broker Option Shares to trading on AIM is expected
to take place at 8.00am on 22 July 2020.
Following the exercise of the Broker Option in respect of
2,875,000 Broker Option Shares, the Company announces that the
Broker Option is now complete with a total of 14,079,165 shares
exercised, raising gross proceeds of approximately GBP1.69 million
for the Company in aggregate.
With the completion of the Broker Option, and subject to
admission of the Firm Placing Shares, Subscription Shares, Retail
Shares and the Broker Option Shares, the Company can confirm that a
total of GBP11.6 million in gross proceeds has been raised;
comprising of a Firm Placing of GBP6.3 million, a Subscription of
GBP2.8 million, a retail offer via the PrimaryBid Platform of
GBP750k and GBP1.69 million via the Broker Option.
Following the admission of the Firm Placing Shares, Subscription
Shares, Retail Shares and the Broker Option Shares, the Company
will have a total of 419,024,611 Ordinary Shares in issue.
Capitalised terms used in this announcement have the meanings
given to them in the announcement of the Fundraise dated 7 July
2020.
For further information, please contact:
e-therapeutics plc Tel: +44 (0)1993 883 125
Ali Mortazavi, Executive Chairman www.etherapeutics.co.uk
Laura Roca-Alonso, Chief Business Officer
Numis Securities Limited Tel: +44 (0) 207 260 1000
Freddie Barnfield/Duncan Monteith (Nominated www.numis.com
Adviser)
James Black (Corporate Broking)
FTI Consulting Tel: +44 (0) 203 727 1000
Simon Conway/Stephanie Cuthbert Email: e-therapeutics@fticonsulting.com
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and access to big
data with expertise in drug discovery and development to transform
the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small sub-sets that are enriched for highly
active hits. Its proprietary platform also has novel applications
in functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
company.
IMPORTANT NOTICES
No action has been taken by the Company, Numis, or any of their
respective affiliates, that would, or which is intended to, permit
a public offer of the new Ordinary Shares in any jurisdiction or
the possession or distribution of this announcement or any other
offering or publicity material relating to the new Ordinary Shares
in any jurisdiction where action for that purpose is required. Any
failure to comply with these restrictions may constitute a
violation of the securities laws of such jurisdictions. Persons
into whose possession this announcement comes shall inform
themselves about, and observe, such restrictions .
No prospectus will be made available in connection with the
matters contained in this announcement and no such prospectus is
required (in accordance with the Prospectus Directive) to be
published.
THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED HEREIN,
IS FOR INFORMATION PURPOSES ONLY, IS NOT INTENDED TO AND DOES NOT
CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO PURCHASE OR
SUBSCRIBE FOR, UNDERWRITE, SELL OR ISSUE OR THE SOLICITATION OF AN
OFFER TO PURCHASE OR SUBSCRIBE, SELL, ACQUIRE, DISPOSE OF THE NEW
ORDINARY SHARES OR ANY OTHER SECURITY IN THE UNITED STATES,
AUSTRALIA, NEW ZEALAND, CANADA, JAPAN OR THE REPUBLIC OF SOUTH
AFRICA OR IN ANY JURISDICTION IN WHICH, OR TO ANY PERSONS TO WHOM,
SUCH OFFERING, SOLICITATION OR SALE WOULD BE UNLAWFUL.
Numis, which is authorised and regulated in the United Kingdom
by the FCA, is acting as nominated adviser, broker and bookrunner
to the Company in relation to the Placing, and is not acting for
any other persons in relation to the Placing. Numis is acting
exclusively for the Company and for no one else in relation to the
matters described in this announcement and is not advising any
other person and accordingly will not be responsible to anyone
other than the Company for providing the protections afforded to
clients of Numis, or for providing advice in relation to the
contents of this announcement or any matter referred to in it. The
responsibilities of Numis as the Company's nominated adviser under
the AIM Rules for Companies and the AIM Rules for Nominated
Advisers are owed solely to London Stock Exchange plc and are not
owed to the Company or to any director or shareholder of the
Company or any other person, in respect of his decision to acquire
shares in the capital of the Company in reliance on any part of
this announcement, or otherwise.
No representation or warranty, express or implied, is or will be
made as to, or in relation to, and no responsibility or liability
is or will be accepted by Numis or the Company or any of their
respective affiliates or any of their respective directors,
officers, employees, advisers or representatives (collectively,
"Representatives") as to or in relation to the accuracy or
completeness of this announcement or any other written or oral
information made available to or publicly available to any
interested party or its advisers, and any liability therefor is
expressly disclaimed.
This announcement does not identify or suggest, or purport to
identify or suggest, the risks (direct or indirect) that may be
associated with an investment in the new Ordinary Shares. Any
investment decision to buy new Ordinary Shares in the Placing must
be made solely on the basis of publicly available information,
which has not been independently verified by Numis. The price of
Ordinary Shares and any income from them may go down as well as up
and investors may not get back the full amount invested on disposal
of the Ordinary Shares. The new Ordinary Shares will not be
admitted to trading on any stock exchange other than AIM, a market
operated by the London Stock Exchange.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSFWFILESSELW
(END) Dow Jones Newswires
July 14, 2020 11:49 ET (15:49 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024